BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231002
DTEND;VALUE=DATE:20231005
DTSTAMP:20260516T071230
CREATED:20230608T110740Z
LAST-MODIFIED:20230608T110740Z
UID:37302-1696204800-1696463999@www.pharmajournalist.com
SUMMARY:5th TIL Therapies Summit
DESCRIPTION:With the first commercial TIL therapy brewing at Iovance\, along with various clinical readouts which are set to come to fruition in 2023\, the race is on for the next generation of modified TIL to enter the clinic. \n \nReturning as the only forum to address bottlenecks in end-to-end TIL development\, the 5th TIL Therapies Summit is designed exclusively for TIL experts to fast-track your program into the clinic and beyond. \nUnite with this niche community across industry and academia as pioneers from Iovance Biotherapeutics\, Turnstone Biologics\, Achilles Therapeutics and Lyell Immunopharma share clinical updates\, next-gen engineering\, and novel innovations to turbocharge preclinical and clinical development of safe\, scalable and effective TIL therapies. \nWith 23+ expert speakers\, 8 new companies and a brand-new Manufacturing & Characterization Bootcamp\, you won’t want to miss this unrivalled opportunity to connect and collaborate with industry leaders. \nDon’t let your team get left behind! Join us as we accelerate the next wave of TIL therapies into the clinic and beyond. Find out more – https://ter.li/mk23q3.
URL:https://www.pharmajournalist.com/event/5th-til-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231009
DTEND;VALUE=DATE:20231011
DTSTAMP:20260516T071230
CREATED:20230810T115308Z
LAST-MODIFIED:20230810T115430Z
UID:37608-1696809600-1696982399@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices Conference & Expo
DESCRIPTION:Wearable Injectors and Connected Devices Conference & Expo \n9 – 10 October 2023 | London\, UK \nhttp://www.wearable-injectors.co.uk/PharmaJournalist-EL \nStrategies to advance digital health and on-body drug devices for large volume delivery \nSAE Media Group are proud to announce the 4th annual Wearable Injectors and Connected Devices conference. As the need for at home self-administration and routes for delivery of time-dependent and high-volume drug delivery grows\, on-body injectors and connected devices hold great opportunity. \nThe conference will delve into on-body device design and development\, enhancing digital connectivity for injectable devices\, strategic approaches to wearable device design\, regulatory considerations and primary container considerations for large volume delivery systems. \nAs part of SAE Media Group’s leading Injectable series of conferences\, we bring together high-level experts from big pharma and device developers to network and share knowledge to advance R&D. The two-day conference will not only bring you high-quality key insights needed to enhance your wearable devices and connected product portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in October 2023! \nBenefits of Attending: \n\nEngage with key regulatory updates surrounding digital health and medical devices\nDiscover advances in device design and development for large volume delivery via on-body injectors\nExplore the key drivers of novel drug products for the development for on-body injectors\nHear insights into the growing potential of digital health to improve patient experience and treatment\nDevelop your understanding of design strategies for connectivity and digital health\n\nDelegates will have the opportunity to network with the following companies: \n\nJohnson & Johnson\nBiogen\nAstraZeneca\nMerck KGaA\nNovartis\nNovo Nordisk\nBoehringer Ingelheim\n\nAnd many more!! \nWho Should Attend: \n\nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of:\nDrug-Delivery Developers\nAutoinjectors\nDevice Engineering\nHuman Factors\nInjectables\nPackaging\nRegulatory Affairs\nConnectivity\nMedical Device Data\nNovel Product Technology\nSmart Device Developers\nDevice Safety Solution Providers\nor anyone who works with Wearable Devices/ On-Body Injectors within pharmaceuticals\, biotech\, device developers and solution providers.\n\nThe two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity\, and a platform for exchanging ideas.
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-conference-expo/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231010
DTEND;VALUE=DATE:20231013
DTSTAMP:20260516T071230
CREATED:20230628T105645Z
LAST-MODIFIED:20230628T105645Z
UID:37366-1696896000-1697155199@www.pharmajournalist.com
SUMMARY:6th Neuropsychiatric Drug Development Summit
DESCRIPTION:The Definitive Industry Forum for Spearheading Non-Psychedelic & Psychedelic R&D \n2023 is booming with novel psychiatric R&D and the promise of precision medicine for neuropsychiatric patients. Pipelines are gaining momentum\, with notable approvals on the horizon\, as unmet needs in PTSD\, bipolar\, anxiety\, schizophrenia\, depression\, and ADHD become greater and greater. There is\, therefore\, a huge deal of novel and promising research to be discussed this October at the 6th Neuropsychiatric Drug Development Summit. \nWith discovery\, preclinical\, translational\, and clinical scientists from the likes of Biogen\, Otsuka\, AbbVie\, Genentech\, Lundbeck\, Delix Therapeutics\, Atai\, Gilgamesh\, and Cerevel Therapeutics\, don’t miss the field’s favorite conference\, specifically dedicated to biopharma’s most pressing challenges of de-risking the translational gap and advancing transformative neuropsychiatric candidates through the clinic. \nTo know more visit: https://ter.li/sar413
URL:https://www.pharmajournalist.com/event/6th-neuropsychiatric-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231020
DTSTAMP:20260516T071230
CREATED:20230524T141827Z
LAST-MODIFIED:20230524T141827Z
UID:37236-1697414400-1697759999@www.pharmajournalist.com
SUMMARY:14th World ADC San Diego 2023
DESCRIPTION:The ADC renaissance shows no sign of slowing down with the ground-breaking approval of ELAHERE for platinum resistant ovarian cancer\, Pfizer’s jaw-dropping acquisition of Seagen for $43 billion\, and BMS’ $1 billion+ pact with Tubulis. There has been no better time to reunite the World ADC community and invest in progressing ADCs to front line treatments for patients. \nThe highly anticipated 14th World ADC San Diego (October 16-19\, 2023 | San Diego\, CA) returns as the world’s largest industry-dedicated discussion and networking forum addressing and overcoming the challenges in end-to-end ADC development. \nGain exclusive access to the full event guide to view the full agenda with 120+ industry-leading speakers. \nWhether you’re new to the field or an ADC guru\, there is something for everyone included in this year’s agenda. Some of your must-attend talks per track include: \n\nDiscovery Chemistry: Join Christopher Marvin\, Principal Research Scientist\, AbbVie as he reviews the design and optimization of glucocorticoid receptor modulator payloads for Immunology ADCs\nCellular Biology: Discuss with Robert Lawrence\, Principal Scientist\, Seagen the influence of artificial intelligence on ADC target discovery\nTranslational: Review a best-in-class translational study with Meijuan Li\, Vice President\, Head of Translational Sciences & Biostatistics\, Eisai Oncology\nClinical Lessons: Be the first to hear industry-changing clinical results from ImmunoGen\, Byondis\, Iksuda Therapeutics\, Seagen\, Bliss Bio\, Genentech and Elucidia Oncology\nProcess and Analytical Development: Debate the key considerations for ADC comparability studies in a dedicated roundtable lead by ADC CMC expert\, Julie Beaudet\, CMC Staff Scientist\, Regeneron Pharmaceuticals\nManufacturing and Supply Chain: Explore the manufacturing of novel dolaLock ADCs with supply chain architecture with Engin Ayturk\, Executive Director\, CMC Process Development\, Mersana Therapeutics\n\nAccess to the complete agenda here including a 7-tracked seminar day and 10 industry-beating workshops. \nDon’t miss out on the chance to reunite with the antibody-drug conjugate community while reflecting on the exciting year that ADCs have had\, and building momentum for the future of this innovative field.
URL:https://www.pharmajournalist.com/event/14th-world-adc-san-diego-2023/
LOCATION:Sheraton San Diego Hotel and Marina\, 1380 Harbor Island Dr\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231019
DTSTAMP:20260516T071230
CREATED:20230718T090856Z
LAST-MODIFIED:20230718T090856Z
UID:37484-1697414400-1697673599@www.pharmajournalist.com
SUMMARY:2nd Operationalise: Early Access Programmes Europe Summit
DESCRIPTION:The Early Access Programmes Summit Europe returns for a second year this October\, aiming to help the industry navigate the notoriously complex European regulatory landscape\, and conquer operational hurdles to provide patients in Europe with early access to medicines. \n \nThis meeting provides a forum to address burning questions and share ideas on topics such as European regulatory guidelines\, labelling\, supply\, and best practices around reimbursement\, integrating of pre- and post-trial access programmes and scoping. \nProviding practical\, valuable case studies is this year’s expert speaker lineup including the likes of GlaxoSmithKline\, Roche\, Novartis\, Sanofi\, and many others! Visit our website to download a free copy of the full event guide to explore the jam-packed 3-day agenda and full speaker faculty. \nWhether you’re a veteran at managing early access programmes and are looking to expand your geo\, or a new entrant to the field\, you’ll leave this conference with the practical lessons and essential connections needed to supercharge your European early access programme across 2023 and beyond. \nTo know more visit: https://bit.ly/3K4BpqO
URL:https://www.pharmajournalist.com/event/2nd-operationalise-early-access-programmes-europe-summit/
LOCATION:Hilton Canary Wharf\, South Quay\, Marsh Wall\, London\, E14 9SH\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231019
DTSTAMP:20260516T071230
CREATED:20230831T083951Z
LAST-MODIFIED:20230905T090233Z
UID:37702-1697414400-1697673599@www.pharmajournalist.com
SUMMARY:4th Commercializing Flow Chemistry Summit
DESCRIPTION:Scaling Flow Chemistry for Sustainability\, Safety and Speed to Market  \nWith the growing demand for better flow technology\, the 4th Commercializing Flow Chemistry Summit is your must-attend meeting to deep-dive into transforming your process efficiency\, emerging technology toolbox and economic gains through strategic flow chemistry. \nWith unmissable case studies from the likes of Novartis\, Boehringer Ingelheim\, Sanofi\, AbbVie\, Eli Lilly and Takeda\, this is the definitive forum to benchmark and learn with this forward-thinking community who reunite once more. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nElevate Sustainability with Industry Leaders: Join forces with Merck\, Eli Lilly and AbbVie to integrate sustainable practices seamlessly into your workflow\, enhancing both environmental responsibility and operational excellence\nUnlock Efficiency through Automation: Discover the power of automation in flow chemistry\, following the footsteps of efficiency leaders like Sanofi\, Takeda\, and Boehringer Ingelheim\, and optimize your processes for peak performance\nMaster Multi-Step Techniques: Gain expert insights from Boehringer Ingelheim on handling multi-step reactions in both flow and batch setups\, fine-tuning your manufacturing processes for maximum efficiency and output\n\nDon’t miss this opportunity to streamline your continuous chemistry research into scaled commercial applications\, and together with 80+ process chemists\, engineers\, and modellers\, go beyond reaction to work up optimization to develop winning processes quicker and expedite your drug development. \nTo know more visit: https://ter.li/jfxs1m
URL:https://www.pharmajournalist.com/event/4th-commercializing-flow-chemistry-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231017
DTEND;VALUE=DATE:20231020
DTSTAMP:20260516T071230
CREATED:20230724T153358Z
LAST-MODIFIED:20230724T153358Z
UID:37509-1697500800-1697759999@www.pharmajournalist.com
SUMMARY:2nd Innate Killer Summit Europe 2023
DESCRIPTION:The 2nd Innate Killer Europe Summit will gather 80+ key European Gamma Delta T\, NK\, iNKT\, neutrophil\, and macrophage developers in October to chase the holy grail of efficacious\, off-the-shelf\, solid tumour immunotherapies through effective and scalable engineering\, engager and combination strategies that promote safe\, potent and persistent innate immune therapies following application. \nDon’t miss this chance to network with innate immune trailblazers from the likes of Sanofi\, Takeda\, Lift Biosciences\, Mink Therapeutics\, Affimed\, Carisma Therapeutics\, Arovella Therapeutics and receive 3-days of some of the best scientific and data driven case studies that will help propel your innate immune therapy into the clinic and beyond. Learn more – https://ter.li/nkcwg3
URL:https://www.pharmajournalist.com/event/2nd-innate-killer-summit-europe-2023/
LOCATION:Crowne Plaza London\, Royal Victoria Dock\, Western Gateway\, London\, E16 1AL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231023
DTEND;VALUE=DATE:20231026
DTSTAMP:20260516T071230
CREATED:20230628T104642Z
LAST-MODIFIED:20230628T104642Z
UID:37361-1698019200-1698278399@www.pharmajournalist.com
SUMMARY:11th IMPACCT: Real World Evidence Summit 2023
DESCRIPTION:Returning for its 11th year\, the IMPACCT: Real World Evidence Summit 2023 will deep dive into the use of RWE for regulatory submissions and clinical trial innovation to unlock unstructured healthcare data and transform disease treatment. \nJoin 100+ senior leaders in RWE\, RWD\, real world analytics & epidemiologists from pharma and biotech to take part in this three-day summit with over 18 hours of exclusive content. \nDon’t miss your unique opportunity to explore how to leverage RWE to target patient populations and drive DE&I into trials. For more information go to: https://ter.li/db1xte
URL:https://www.pharmajournalist.com/event/11th-impacct-real-world-evidence-summit-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231023
DTEND;VALUE=DATE:20231025
DTSTAMP:20260516T071230
CREATED:20230810T114239Z
LAST-MODIFIED:20230810T114239Z
UID:37598-1698019200-1698191999@www.pharmajournalist.com
SUMMARY:Biosensors for Medical Wearables Conference and Expo
DESCRIPTION:Biosensors for Medical Wearables Conference and Expo  \n*In collaboration with Medical Design Briefs* \nOctober 23-24\, 2023 | Boston\, MA\, USA \nhttp://www.biosensors-medical-wear.com/PharmaJournalist-WL \nSAE Media Group’s 3rd Annual Biosensors for Medical Wearables Conference will be back for 2023 in Boston to bring together device developers\, MedTech\, component manufacturers and big pharma to share and discuss the exciting advances in the medical wearable technology landscape. \nThe wearable biosensors market has grown significantly in recent years leading to increasingly growing potential for medical applications and at home alternatives for patients. With growing applications and potential in remote patient monitoring\, diagnosis\, therapeutics and detection of disease\, wearable sensors are attracting considerable interest due to their opportunities in better supporting patients\, clinical outcomes and decisions. Furthermore\, AI and connected technologies are furthering the potential opportunities of this industry. However\, challenges including flexibility of wearable devices\, the collection of clinical-grade data and advanced battery technologies still remain for the industry to overcome. This year’s conference looks to address these hot topics through case studies and industry insights. \nThis is a must attend event\, giving you the chance to engage in the latest innovations that are accelerating the wearable biosensors industry. We hope to welcome you in October 2023! \nReasons to attend: \n\nBenchmark against and explore the latest biosensor technologies for wearable medical devices from Abbott\, Empatica and Hexoskin\nDelve into the potential of wearable sensors and digital tools in decentralized diagnosis including a Johnson & Johnson case study on the Heartline project\nLearn how game changing companies such as Philips and Medtronic are utilizing wearables to maximize remote patient monitoring opportunities for wider patient populations\nExplore how AI and machine learning technologies are enabling optimized data collection and streamlined data analysis\nDiscover cutting-edge biosensor therapeutic applications for neurology with Neurasantys and a panel discussion on future medical opportunities\n\nWho you can meet? \n\nAndreas Caduff\, Strategic Advisory Board\, DiME\nLorelie Villarete\, Manager\, Clinical Affairs\, Lingo Sensing Technology Unlimited Company (an Abbott Company)\nTim Callahan\, VP Scientific Affairs\, Philips\nKara Chappie\, Director and Project Lead\, Pfizer\nJason Case\, Vice President\, Research and Development\, Patient Monitoring\, Medtronic\nJames Mault\, MD\, Founder and CEO\, BioIntellisense\, Inc.\nJasmin Imsirovic\, Associate Director\, Takeda\nJanet Nikolovski\, New Venture Lead – Genitourinary Oncology\, Johnson & Johnson
URL:https://www.pharmajournalist.com/event/biosensors-for-medical-wearables-conference-and-expo/
LOCATION:COURTYARD BY MARRIOTT BOSTON DOWNTOWN\, 275 Tremont St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231030
DTEND;VALUE=DATE:20231102
DTSTAMP:20260516T071230
CREATED:20230803T103923Z
LAST-MODIFIED:20230803T103923Z
UID:37564-1698624000-1698883199@www.pharmajournalist.com
SUMMARY:CRISPR-Based Therapy Analytical Development Summit
DESCRIPTION:CRISPR-based therapies are undergoing a remarkable evolution\, with drug developers striving to enhance the safety\, precision and efficacy of their products. As this paradigm takes place\, more complex CRISPR structures necessitate cutting-edge advancements in analytical methods and tools to effectively characterize the genome-edited products utilizing CRISPR technology. \nAs industry experts tread unchartered territory\, the inaugural CRISPR-Based Therapy Analytical Development Summit has been convened\, gathering more than 60 distinguished experts in analytical development devoted to the creation\, refinements and implementation of more robust analytical tools specifically tailored to CRISPR-based constructs. \nWithin this intimate space\, we will adopt a shared consensus and delve into a comprehensive array of analytical techniques central to any CRISPR-based toolkit. Topics of discussion will span pioneering technology that includes everything from novel methods to characterize the guide RNA and whole CRISPR complex\, to the use of next-generation sequencing (NGS) to detect and assess off-targets for superior safety evaluations. \nIn response to the regulatory bodies’ insistence on high-quality data to substantiate the safety and efficacy of genome-edited products\, this summit is imperative to all individual engaged in the development of analytical tools and methodologies utilizing CRISPR technology as we build for better guidance around CRISPR-edited products. \nIf your role centers around analytical expertise and gene edited specialization\, this meeting will enable you to streamline your analytical development process and connect in a shared goal to deliver safer therapies\, with superior therapeutic benefit to patients faster. \nTo know more visit: https://ter.li/28jg6x
URL:https://www.pharmajournalist.com/event/crispr-based-therapy-analytical-development-summit/
LOCATION:Hilton Boston Bay Back\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR